ES2171203T3 - Composiciones que contienen lazaroides y su uso para prevenir adherencias. - Google Patents

Composiciones que contienen lazaroides y su uso para prevenir adherencias.

Info

Publication number
ES2171203T3
ES2171203T3 ES95939168T ES95939168T ES2171203T3 ES 2171203 T3 ES2171203 T3 ES 2171203T3 ES 95939168 T ES95939168 T ES 95939168T ES 95939168 T ES95939168 T ES 95939168T ES 2171203 T3 ES2171203 T3 ES 2171203T3
Authority
ES
Spain
Prior art keywords
sub
formula
preferibly
lipid
independently represent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95939168T
Other languages
English (en)
Inventor
Kathleen E Rodgers
Gere S Dizerega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of ES2171203T3 publication Critical patent/ES2171203T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSICIONES Y METODOS PARA MINIMIZAR O PREVENIR LA FORMACION DE ADHESIONES, EN LOS QUE UNA CANTIDAD EFECTIVA DE AL MENOS UN COMPUESTO LAZAROIDE, PREFERIBLEMENTE UNO DE LA FORMULA GENERAL (I), EN LA QUE R REPRESENTA UNA FORMULA (IA) O (IB), O DE LA FORMULA (II), DONDE R REPRESENTA H O CH{SUB,3}; ; R{SUB,1} REPRESENTA LA FORMULA (IA) O LA FORMULA (IIA), DONDE R{SUB,2}, R{SUB,3}, R{SUB,4} Y R{SUB,5} INDEPENDIENTEMENTE REPRESENTAN H O NR{SUB,6}R{SUB,7}, DONDE R{SUB,6} Y R{SUB,7} INDEPENDIENTEMENTE REPRESENTAN H Y C{SUB,1}-C{SUB,6} ALQUIL Y QUE SE ADMINISTRA POR UN PERIODO DE TIEMPO SUFICIENTE PARA PERMITIR LA REPARACION DE TEJIDO. EL COMPUESTO DE LAS FORMULAS GENERALES (I) O (II) SE ADMINISTRA PREFERIBLEMENTE JUNTO CON UN VEHICULO DE SUMINISTRO ( P.E. MICROCAPSULAS, MICROESFERAS, PELICULAS POLIMERICAS BIODEGRADABLES, SISTEMAS DE SUMINISTRO DE BASE LIPIDICA COMO LIPOSOMAS Y ESPUMAS LIPIDICAS, INSTILADOS VISCOSOS Y BARRERAS MECANICAS ABSORBIBLES) UTILES PARA MANTENER CONCENTRACIONES LOCALES DELCOMPUESTO A UN NIVEL EFECTIVO.
ES95939168T 1994-11-17 1995-11-15 Composiciones que contienen lazaroides y su uso para prevenir adherencias. Expired - Lifetime ES2171203T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/341,651 US5614515A (en) 1994-11-17 1994-11-17 Lazaroid-based compositions and method for preventing adhesion formation using the same

Publications (1)

Publication Number Publication Date
ES2171203T3 true ES2171203T3 (es) 2002-09-01

Family

ID=23338469

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95939168T Expired - Lifetime ES2171203T3 (es) 1994-11-17 1995-11-15 Composiciones que contienen lazaroides y su uso para prevenir adherencias.

Country Status (9)

Country Link
US (1) US5614515A (es)
EP (1) EP0792153B1 (es)
JP (1) JPH10511645A (es)
AT (1) ATE214932T1 (es)
AU (1) AU692641B2 (es)
CA (2) CA2205347C (es)
DE (1) DE69526108T2 (es)
ES (1) ES2171203T3 (es)
WO (1) WO1996015795A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10505063A (ja) * 1994-09-01 1998-05-19 ファルマシア・アンド・アップジョン・カンパニー チリラザドの共溶媒非経口処方
US5866554A (en) * 1996-07-19 1999-02-02 Shalaby; Shalaby W. Compositions for prevention of inflammation and adhesion formation and uses thereof
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
CA2288913C (en) * 1997-04-22 2004-07-13 Friedrich Lampert Membrane system for controlled tissue regeneration in cases of diseases of the peridontium
WO1999046285A2 (en) 1998-03-11 1999-09-16 University Of Southern California Method of promoting production of living tissue equivalents
US6762167B1 (en) 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
CA2322963C (en) 1998-05-11 2004-04-13 University Of Southern California Methods to increase white blood cell survival after chemotherapy
DK1085920T3 (da) * 1998-05-13 2002-04-15 Ml Lab Plc Dextrinholdigt præparat til forebyggelse af kirurgiske adhæsioner
GB9810127D0 (en) 1998-05-13 1998-07-08 Ml Lab Plc Prevention of surgical adhesions
US6916783B2 (en) 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
CA2328871C (en) 1998-07-13 2002-10-01 University Of Southern California Methods for accelerating bone and cartilage growth and repair
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6800298B1 (en) 2000-05-11 2004-10-05 Clemson University Biological lubricant composition and method of applying lubricant composition
ES2427930T3 (es) * 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
WO2002094321A1 (fr) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions favorisant la guérison d'une fracture osseuse
US20090227507A1 (en) * 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987001706A2 (en) * 1985-09-12 1987-03-26 The Upjohn Company C20 through c26 amino steroids
IN166447B (es) * 1985-11-27 1990-05-12 Ethicon Inc
US4968675A (en) * 1988-10-28 1990-11-06 Upjohn Non-hemolytic lazaroid parenteral formulation
US5256408A (en) * 1990-06-12 1993-10-26 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use

Also Published As

Publication number Publication date
EP0792153A1 (en) 1997-09-03
AU4110796A (en) 1996-06-17
US5614515A (en) 1997-03-25
CA2625906C (en) 2010-02-09
WO1996015795A1 (en) 1996-05-30
CA2625906A1 (en) 1996-05-30
DE69526108D1 (de) 2002-05-02
DE69526108T2 (de) 2002-11-21
ATE214932T1 (de) 2002-04-15
EP0792153B1 (en) 2002-03-27
JPH10511645A (ja) 1998-11-10
CA2205347C (en) 2008-10-21
AU692641B2 (en) 1998-06-11
CA2205347A1 (en) 1996-05-30

Similar Documents

Publication Publication Date Title
ES2171203T3 (es) Composiciones que contienen lazaroides y su uso para prevenir adherencias.
AR002740A1 (es) Compuesto derivado de la isotiazolona y formulacion farmaceutica con el mismo.
ES2183905T3 (es) Inhibidores de metaloproteasa de matriz.
AR245932A1 (es) Un proceso para la preparacion de derivados del acido 3-acilamino-2-oxo-azetidin-1-sulfonico y sus sales.
AR018844A1 (es) Composicion desinfectante y proceso para desinfectar superficies
ES2042218T3 (es) Compuesto de aceite refrigerante.
ES2323952T3 (es) 3-aminopirazol triciclicos sustituidos en n como inhibidores receptores de pdfg.
AR011093A1 (es) Compuestos derivados de sulfonil urea, composicion farmaceutica que los contiene y procedimiento para su uso.
PE2799A1 (es) Lactamas e imidas heterociclicas de aralquilo y aralquilideno
ATE90688T1 (de) Trh-derivate, deren herstellung und pharmazeutische zusammensetzungen.
ES2102668T3 (es) Composiciones detergentes liquidas que contienen proteasa y ciertos acidos y esteres beta-aminoalquilboronicos.
CO5040184A1 (es) Composiciones granulares acetonitril amonio n-alquilos
ES2171022T3 (es) Esteres de etilenglicol de derivados de monohidrobenzoporfirinas como agentes fotoactivos.
ES2101223T3 (es) Composicion de aciete de refrigerador para refrigerante de fluoroalcano.
AR033852A1 (es) Mezcla de estabilizadores para la estabilizacion de polimeros con un contenido de cloro, composicion que la comprende, procedimiento para la estabilizacion de polimeros con un contenido de cloro y articulos de consumo que contienen un pvc
AR020250A1 (es) Compueto de isoxazolinona, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
FR2672598B1 (es)
UY25986A1 (es) Complejo del inhibidor de ras-farnesiltransferasa y sulfobutiléter-7-beta-ciclodextrina o 2-hidroxipropil-beta-ciclodextrina y método.
AR012426A1 (es) Un compuesto de indazol amida, un procedimiento para prepararlo, compuestos intermediarios, y una composicion farmaceutica que comprende dicho compuesto de indazol amida.
ES2062443T3 (es) Nuevos derivados peptidicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2158077T3 (es) Carboxanilidas oxidiacinicas artropodicidas.
ES2142642T3 (es) Dispersiones de poliuretano acuosas latentemente reticulantes.
ES2123812T3 (es) Derivados 1,5-benzodiazepina utiles como antagonistas de las cck o de la gastrina.
ES2092116T3 (es) Policarbonatos y sus usos para la preparacion de matrices bioerosionables.
MX9306679A (es) Penems 6-(metilen-sustituidos), derivados de los mismos, proceso para su preparacion y composicion farmaceutica que los contiene.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 792153

Country of ref document: ES